Assenagon Asset Management S.A. raised its holdings in shares of Celgene Co. (NASDAQ:CELG) by 31.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 132,659 shares of the biopharmaceutical company’s stock after buying an additional 31,849 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Celgene were worth $13,844,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Thompson Davis & CO. Inc. raised its stake in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI raised its stake in shares of Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares in the last quarter. Robecosam AG acquired a new position in shares of Celgene in the third quarter valued at $114,000. Guidant Wealth Advisors acquired a new position in shares of Celgene in the third quarter valued at $119,000. Finally, Capital Bank & Trust Co raised its stake in shares of Celgene by 166.8% in the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 517 shares in the last quarter. Institutional investors own 77.84% of the company’s stock.
Shares of Celgene Co. (CELG) opened at $95.61 on Friday. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99. The company has a market capitalization of $71,920.00, a price-to-earnings ratio of 18.21, a PEG ratio of 0.66 and a beta of 1.49. Celgene Co. has a 1-year low of $88.32 and a 1-year high of $147.17.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.78 by $0.09. The company had revenue of $3.48 billion for the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business’s revenue for the quarter was up 16.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.61 earnings per share. research analysts expect that Celgene Co. will post 7.68 EPS for the current fiscal year.
Celgene announced that its Board of Directors has approved a stock repurchase program on Wednesday, February 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
CELG has been the subject of a number of recent research reports. Cantor Fitzgerald restated a “hold” rating and issued a $112.00 target price on shares of Celgene in a research note on Monday, October 30th. Oppenheimer restated a “buy” rating and issued a $166.00 target price (up from $163.00) on shares of Celgene in a research note on Monday, October 30th. Mizuho restated a “buy” rating on shares of Celgene in a research note on Friday, November 3rd. Canaccord Genuity set a $140.00 target price on Celgene and gave the company a “buy” rating in a research note on Thursday, November 16th. Finally, BMO Capital Markets upped their target price on Celgene from $148.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, November 17th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $130.25.
In other Celgene news, insider Mark J. Alles bought 3,260 shares of the firm’s stock in a transaction dated Thursday, February 8th. The shares were bought at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the acquisition, the insider now owns 178,904 shares of the company’s stock, valued at $16,441,277.60. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $95.99, for a total value of $887,907.50. Following the sale, the director now owns 94,801 shares in the company, valued at approximately $9,099,947.99. The disclosure for this sale can be found here. 0.95% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Celgene Co. (CELG) Shares Bought by Assenagon Asset Management S.A.” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/02/25/celgene-co-celg-shares-bought-by-assenagon-asset-management-s-a.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.